Figures & data
Table 1 Characteristics of studies included in the meta-analysis
Figure 2 Forest plot of studies evaluating the relationship between HSP27 expression and clinicopathological features: (A) expression; (B) lymph node metastasis; (C) serosal invasion; (D) gender; (E) tumor size; (F) differentiation; (G) TNM stage.
Abbreviations: OR, odds ratio; CI, confidence interval.
![Figure 2 Forest plot of studies evaluating the relationship between HSP27 expression and clinicopathological features: (A) expression; (B) lymph node metastasis; (C) serosal invasion; (D) gender; (E) tumor size; (F) differentiation; (G) TNM stage.](/cms/asset/8f94a49c-b05c-4608-9f18-1c19c6c4f2a0/dott_a_12195694_f0002_b.jpg)
![Figure 2 Forest plot of studies evaluating the relationship between HSP27 expression and clinicopathological features: (A) expression; (B) lymph node metastasis; (C) serosal invasion; (D) gender; (E) tumor size; (F) differentiation; (G) TNM stage.](/cms/asset/399a95f6-09a3-4b4d-a2e5-c6b5e4ecb7a1/dott_a_12195694_f0002a_c.jpg)
Table 2 HSP27 clinicopathological features for gastric carcinoma
Figure 3 Begg’s publication bias plot for HSP27 related studies: (A) expression; (B) lymph node metastasis; (C) serosal invasion; (D) gender; (E) tumor size; (F) differentiation; (G) TNM stage.
![Figure 3 Begg’s publication bias plot for HSP27 related studies: (A) expression; (B) lymph node metastasis; (C) serosal invasion; (D) gender; (E) tumor size; (F) differentiation; (G) TNM stage.](/cms/asset/b20589bd-fca2-4112-a87f-88082d1fc411/dott_a_12195694_f0003_b.jpg)
![Figure 3 Begg’s publication bias plot for HSP27 related studies: (A) expression; (B) lymph node metastasis; (C) serosal invasion; (D) gender; (E) tumor size; (F) differentiation; (G) TNM stage.](/cms/asset/1cfbb54c-fde7-496b-9725-fe3d43f0b91d/dott_a_12195694_f0003a_b.jpg)
Table 3 Subgroup analysis of expression, lymph node metastasis, tumor size, and differentiation